布地奈德混悬液雾化维持治疗重度持续性哮喘疗效与安全性观察

目的：评价布地奈德混悬液雾化吸入治疗重度持续性哮喘病人8周的疗效和安全性。方法：重度持续性哮喘病人24例，筛选后给予雾化吸入布地奈德混悬液8周，收集治疗4周、8周后肺功能（FEV1）、症状评分、沙丁胺醇气雾剂（万托林）使用情况，分别与治疗前进行比较，观察尿皮质醇水平的变化及副作用情况。结果：21例病人筛选成功，20例完成治疗，治疗后4周、8周的FEV1、症状评分、万托林使用情况较前改善（P〈0．05）。治疗后第4、8周FEV1分别改善12．7％、13．7％，日间症状评分分别改善31．3％、29．8％，夜间症状评分分别改善32．8％、36．8％，每日使用万托林的次数分别减少39．1％、41．2％，治疗后病人的尿皮质醇在正常范围内，整个治疗过程中无严重副作用发生。结论：布地奈德混悬液维持治疗重度持续性哮喘病人有效，且安全性好。

Nebulized Budesonide suspension in maintenance therapy of patients with severe persistent asthma

AIM： To observe the curative effect and safety of Budesonide inhalation suspension （BIS） in maintenance therapy of patients with severe persistent asthma . METHODS： 24 patients with severe asthma were screened, the patients enrolled were treated with BIS 2 mg twice a day and salbutamol aerosol as need for 8 weeks. The curative effect outcomes after 4 treating weeks and 8 treating weeks, including pulmonary {unction test （FEV1）, asthma symptom scores, salbutamol aerosol use, as well as the side effects index at the end of study, such as urocortisol level, were collected and compared before study （baseline）. RESULTS： 21 patients were successfully enrolled, 20 of which completed the treatment. The curative effect outcomes were improved compared with the baseline（P〈0.05）, FEV1 was improved by 12.7% and 13.7 %, daytime symptom scores were improved by 31.3% and 29.8%, night symptom scores were improved by 32.8% and 36.8%, times of Ventolin daily use were reduced by 39.1% and 41.2% after 4 weeks treatment and 8 weeks treatment respectively. After 8 weeks treatment, urocortisol in all patients was normal range and no severe side effect occurred. CONCLUSION. BIS has good curative effect and safety in treating patients with severe persistent asthma as maintenance therapy.